Loading
Life sciences · Journal article
International Journal of Cancer · September 15, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Human papillomavirus (HPV) is the necessary cause of cervical cancer and responsible for ~90% of anal, 78% of vaginal, 50% of penile, and 25% of vulvar cancers. In Costa Rica (CR), few studies have examined incidence trends of these cancers. We assessed age-standardized incidence rates (ASIRs) and trends of invasive anogenital cancers. Incidence data were obtained from the CR National Registry of Tumors and population estimates from the National Institute of Statistics and Census. ASIRs (1960-Segi World population) were calculated using Surveillance, Epidemiology, and End Results (SEER)*Stat, and trends and annual percent changes (APCs) using Joinpoint regression. During 1996-2022, 10,022 invasive anogenital cancer cases were included in the analysis; of which 8122 (81.0%) were cervical. Cervical cancer incidence declined significantly (APC: -3.2%, 95% confidence interval [CI]: -3.9, -2.5). Vaginal cancer showed a non-statistically significant increase (APC: 0.8%, 95% CI: -1.6, 4.1), while vulvar and penile cancers presented a non-statistically significant decrease (APC: -0.8, 95% CI: -1.9, 0.4, and -0.8, 95% CI: -2.1, 1.0, respectively). Anal cancer incidence remained stable (APC: 0.2, 95% CI: -0.9, 1.8) and was 1.4 times higher in females than males (5.3 and 3.7 per million, respectively). In males, penile cancer incidence was 3-times higher than anal cancer (10.9 vs. 3.7 per million). Non-cervical anogenital cancers were rare and showed varying trends. Cervical cancer remains a public health concern in CR, requiring stronger prevention. Research on vaccine-covered HPV genotypes and continued surveillance of anogenital cancers are needed to assess prevention impact.